Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2009132320 A2 2009-10-29 [WO2009132320]WO2009132320 A3 2010-01-07 [WO2009132320] / 2009-10-292010-01-07
申请号/申请日
2009WO-US41736 / 2009-04-24
发明人
LONGO VALTER;
申请人
UNIVERSITY OF SOUTHERN CALIFORNIA;
主分类号
IPC分类号
A01N-043/50A61K-031/415
摘要
(WO2009132320) The present invention relates to dietary compositions comprising reduced level of methionine, tryptophan, all amino acids, or protein, dietary compositions comprising glycerol as a substitute for monosaccharides, disaccharides, and polysaccharides, and hypocaloric or calorie free diets with reduced level of energy, carbohydrates, or protein.  Also disclosed are methods of using these compositions and diets, as well as fasting, to protect subjects against chemotherapy, radiotherapy, oxidative stress, or aging.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2008US-61047680 2008-04-24
主权利要求
(WO2009132320) WHAT IS CLAIMED IS: 1. A dietary composition comprising: 0-0.2% (by weight) L- methionine; L-tryptophan, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L- threonine, and L-valine in the amount of at least 0.05% (by weight) each; and no protein. 2. The composition of claim 1, further comprising one or more amino acids selected from the group consisting of L-alanine, L-asparagine, L- aspartic acid, L-cysteine, L-glutamatic acid, L-glutamine, L-glycine, L- proline, L-serine, L-tyrosine, L-arginine, and L-histidine. 3. A method of protecting an animal or human against chemotherapy, comprising administering the composition of claim 1 to an animal or human, thereby protecting the animal or human against chemotherapy. 4. The method of claim 3, further comprising exposing the animal or human to the chemotherapy. 5. The method of claim 4, wherein the composition is administered to the animal or human for 3-10 consecutive days prior to the exposing step, 24 hours following the exposing step, or a combination thereof. 6. A dietary composition comprising: 0-0.2% (by weight) L-tryptophan; L-methionine, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L- threonine, L-valine in the amount of at least 0.05% (by weight) each; and no protein. 7. The composition of claim 6, further comprising one or more amino acids selected from the group consisting of L-alanine, L-asparagine, L- aspartic acid, L-cysteine, L-glutamatic acid, L-glutamine, L- glycine, L- proline, L-serine, L-tyrosine, L-arginine, and L-histidine. 8. A method of protecting an animal or human against chemotherapy, comprising administering the composition of claim 6 to an animal or human, thereby protecting the animal or human against chemotherapy. 9. The method of claim 8, further comprising exposing the animal or human to the chemotherapy. 10. The method of claim 9, wherein the composition is administered to the animal or human for 3-10 consecutive days prior to the exposing step, 24 hours following the exposing step, or a combination thereof. 11. A dietary composition comprising: L-methionine, L-tryptophan, L-isoleucine, L-leucine, L-lysine, L- phenylalanine, L-threonine, L-valine, L-alanine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamatic acid, L-glutamine, L-glycine, L-proline, L- serine, L-tyrosine, L-arginine, and L-histidine in the amount of 0-0.2% (by weight) each; and no protein. 12. A method of protecting an animal or human against chemotherapy, radiotherapy, oxidative stress, or aging, comprising administering the composition of claim 11 to an animal or human, thereby protecting the animal or human against chemotherapy, radiotherapy, oxidative stress, or aging. 13. The method of claim 12, further comprising exposing the animal or human to the chemotherapy, radiotherapy, or oxidative stress. 14. The method of claim 13, wherein the composition is administered to the animal or human for 3-10 consecutive days prior to the exposing step, 24 hours following the exposing step, or a combination thereof. 15. The method of claim 12, wherein the composition is administered every third meal or every 3-10 days to protect the animal or human against aging. 16. A dietary composition comprising glycerol as a substitute for monosaccharides, disaccharides, and polysaccharides. 17. A method of protecting an animal or human against chemotherapy or oxidative stress, comprising administering the composition of claim 16 to an animal or human, thereby protecting the animal or human against chemotherapy or oxidative stress. 18. The method of claim 17, further comprising exposing the animal or human to the chemotherapy or oxidative stress. 19. The method of claim 18, wherein the composition is administered to the animal or human for 3-10 consecutive days prior to the exposing step, 24 hours following the exposing step, or a combination thereof. 20. A hypocaloric or calorie free diet comprising: dietary materials capable of providing nutrition to a human subject while providing no more than 813-957 kcal total energy, no more than half of which is in carbohydrates if the carbohydrates are present in the dietary materials, wherein the dietary materials include no more than 30-36 g protein. 21. The diet of claim 20, wherein the dietary materials are capable of providing no more than 700 kcal total energy. 22. A method of protecting an animal or human against chemotherapy, radiotherapy, oxidative stress, or aging, comprising: administering to an animal or human a diet capable of providing nutrition while providing no more than 11 kcal energy per kg body weight of the animal or human per day, and no more than 0.4 g protein per kg body weight of the animal or human per day, thereby protecting the animal or human against chemotherapy, radiotherapy, oxidative stress, or aging, wherein no more than half of the energy is in carbohydrates if the carbohydrates are present in the diet. 23. The method of claim 22, wherein the diet is capable of providing no more than 700 kcal total energy per day. 24. The method of claim 22, further comprising exposing the animal or human to the chemotherapy, radiotherapy, or oxidative stress. 25. The method of claim 24, wherein the diet is administered to the animal or human for 3-10 consecutive days prior to the exposing step, 24 hours following the exposing step, or a combination thereof. 26. The method of claim 22, wherein the diet is administered every third meal or every 3-10 days to protect the animal or human against aging. 27. A method of protecting an animal or human against chemotherapy, comprising: fasting an animal or human suffering from cancer for 48-140 hours prior to one round of chemotherapy, 4-56 hours following the chemotherapy, or a combination thereof; and exposing the animal or human to the chemotherapy. 8. The method of claim 27, wherein the animal or human is fasted foro more than 180 hours prior to and following one round of chemotherapy.
法律状态
(WO2009132320) LEGAL DETAILS FOR WO2009132320  Actual or expected expiration date=2011-10-24    Legal state=DEAD    Status=LAPSED     Event publication date=2009-04-24  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2009041736  Application date=2009-04-24  Standardized application number=2009WO-US41736     Event publication date=2009-10-29  Event code=WO/A2  Event type=Examination events  International application published with declaration under Article 17 (2) (a)  Publication country=WO  Publication number=WO2009132320  Publication stage Code=A2  Publication date=2009-10-29  Standardized publication number=WO2009132320     Event publication date=2010-01-07  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO2009132320  Publication stage Code=A3  Publication date=2010-01-07  Standardized publication number=WO2009132320     Event publication date=2010-03-25  Event code=WO/DPE1  Event type=Examination events  Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)    Event publication date=2011-10-24  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE CA2722365  Actual or expected expiration date=2029-04-24    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2722365  Application date in the designated or member state=2009-04-24   Application number in the designated or member state=2009CA-2722365 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2722365  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2009-10-29   Publication number in the designated or member state=CA2722365    Event publication date=2010-10-22  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2010-10-26    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2010-10-26  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP2285218  Actual or expected expiration date=2029-04-24    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=EP Corresponding appl: EP09734637  Application date in the designated or member state=2009-04-24   Application number in the designated or member state=2009EP-0734637 Corresponding cc:  Designated or member state=EP Corresponding pat: EP2285218  Publication stage code in the designated or member state=A2  Publication date in the designated or member state=2011-02-23   Publication number in the designated or member state=EP2285218    Event publication date=2009-12-23  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE JP2011523626  Actual or expected expiration date=2015-08-04    Legal state=DEAD    Status=REVOKED   Corresponding cc:  Designated or member state=JP Corresponding appl: JP2011506488  Application date in the designated or member state=2009-04-24   Application number in the designated or member state=2011JP-0506488 Corresponding cc:  Designated or member state=JP Corresponding pat: JP2011523626  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2011-08-18   Publication number in the designated or member state=JP2011523626    Event publication date=2010-10-22  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=JP     Event publication date=2015-08-05  Event code=JP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=JP
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部